Several other equities analysts also recently weighed in on the company. Cowen reiterated a buy rating and set a $18.00 target price on shares of Epizyme in a research report on Tuesday, February 26th. Oppenheimer cut their price objective on Epizyme from $27.00 to $18.00 and set an outperform rating on the stock in a report on Wednesday, February 27th. Roth Capital restated a buy rating on shares of Epizyme in a report on Wednesday, February 27th. ValuEngine upgraded Epizyme from a sell rating to a hold rating in a report on Wednesday, February 27th. Finally, Zacks Investment Research upgraded Epizyme from a hold rating to a buy rating and set a $14.00 price objective on the stock in a report on Tuesday, April 30th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $18.90.
NASDAQ EPZM opened at $14.03 on Tuesday. Epizyme has a twelve month low of $5.14 and a twelve month high of $16.95. The stock has a market cap of $1.27 billion, a P/E ratio of -8.16 and a beta of 2.72. The company has a current ratio of 12.55, a quick ratio of 12.55 and a debt-to-equity ratio of 0.03.
Institutional investors have recently added to or reduced their stakes in the company. Exane Derivatives bought a new position in Epizyme during the first quarter worth about $84,000. Quantamental Technologies LLC bought a new position in Epizyme during the fourth quarter worth about $43,000. Legal & General Group Plc grew its holdings in Epizyme by 16.9% during the fourth quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,455 shares during the period. Principal Financial Group Inc. bought a new position in Epizyme during the first quarter worth about $135,000. Finally, Two Sigma Advisers LP bought a new position in Epizyme during the fourth quarter worth about $76,000. Institutional investors own 84.14% of the company’s stock.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
See Also: Initial Public Offering (IPO)
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.